Table 1.
PICOS strategy for clinical evidence of dalbavancin in ABSSSI.
Fig 1.
PRISMA flow diagram with the clinical studies identified through the predefined search strategy.
Fig 2.
Network of the studies used in the meta-analysis.
Abbreviations: DAL: dalbavancin; DAP: daptomycin; LZD: linezolid; TEI: teicoplanin; VAN: vancomycin; TIG: tigecycline. *Includes studies where the comparator was vancomycin, vancomycin plus aztreonam. Or vancomycin plus conventional treatment. Each node represents a treatment and the connecting lines indicate pairs of treatments that have been directly compared in one RCT. The numbers in the connecting lines indicate the number of relevant studies for each treatment comparison.
Table 2.
Summary information of all RCTs included in the network meta-analysis.
Table 3.
Clinical trials included in the network meta-analysis.
Table 4.
Model fit statistics for all endpoints and patient subgroups.
Table 5.
Heterogeneity for the different pairwise meta-analyses used in the network meta-analysis.
Table 6.
Results for the efficacy and safety-related endpoints from the network meta-analysis.
Fig 3.
Forest plot on a log scale of the Odds ratios between dalbavancin and all other treatments for discontinuation due to AEs/SAEs for adults only (Odds ratio >1 favours DAL).